OOIR: Observatory of International Research

Papers

(The H4-Index of European Neuropsychopharmacology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables	259
The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: A critical review across waves	258
Results of the COVID-19 mental health international for the general population (COMET-G) study	88
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study	72
Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience	67
Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis	64
Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis	63
Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses	53
Ethical considerations for precision psychiatry: A roadmap for research and clinical practice	50
Stratified psychiatry: Tomorrow's precision psychiatry?	47
Brain-immune crosstalk in the treatment of major depressive disorder	45
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials	43
Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis	39
Rapid response to selective serotonin reuptake inhibitors in post-COVID depression	39
Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls	38
Transcranial direct current stimulation in Autism Spectrum Disorder: A systematic review and meta-analysis	37
The elephant in the room: Medication as confounder	37
Epidemiology and costs of depressive disorder in Spain: the EPICO study	36
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions	36
No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial	36
Trajectory of cognitive impairments over 1 year after COVID‐19 hospitalisation: Pattern, severity, and functional implications	35
Predictors of serious suicidal behavior in late-life depression	33
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders	33
Anterior cingulate cortex neurometabolites in bipolar disorder are influenced by mood state and medication: A meta-analysis of 1H-MRS studies	33
Application of transcranial magnetic stimulation for major depression: Coil design and neuroanatomical variability considerations	32

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?	31
Higher baseline interleukin-1β and TNF-α hamper antidepressant response in major depressive disorder	30
Mind long COVID: Psychiatric sequelae of SARS-CoV-2 infection	29
Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder	29